Purpose: To evaluate the survival outcomes of patients with intermediate to advanced hepatocellular carcinoma (HCC), patients who underwent transarterial chemoembolization (TACE) alone were compared with those who underwent a combination of TACE and ablation therapy.
Patients And Methods: This study retrospectively evaluated 536 HCC patients in our hospital from July 2016 to November 2022. All patients underwent TACE, with a subset also receiving ablation therapy. To ensure comparability, propensity score matching (PSM) was performed. We then compared overall survival (OS) and progression-free survival (PFS) between these two groups. Survival outcomes were analyzed utilizing Kaplan-Meier curves and compared via the Cox regression.
Results: 200 among these 536 HCC patients received TACE combined with ablation whereas the remaining 336 received TACE alone. With PFS analysis, the numbers were reduced to 176 in combination therapy group and 250 in TACE alone group. With and without PSM, the OS and PFS were consistently and significantly better in the former than the latter group. In patients with Barcelona Clinic Liver Cancer (BCLC) stage B or C, those who received combination therapy demonstrated significantly higher OS compared to those treated with TACE alone. For stage B patients, PFS was also significantly longer in the combination therapy group, before and after PSM [hazard ratio (HR), 0.563; 95% CI: 0.360-0.879; = 0.012, HR, 0.613; 95% CI: 0.382-0.985; = 0.043]. However, after PSM, no statistical difference in survival outcomes was observed between the two groups for stage C patients (HR, 0.673; 95% CI: 0.395-1.146; = 0.145).
Conclusion: Our data suggested that for OS, the combination therapy has sustained benefits for both patients with stage B and C, But for PFS, the benefits of the combination therapy among the stage C patients, could not be persistently demonstrated by the current datasets.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11890005 | PMC |
| http://dx.doi.org/10.2147/CMAR.S511364 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Delayed inflammatory nodule from predominantly low-molecular-weight hyaluronic acid filler secondary to COVID-19 infection.
J Cosmet Laser Ther
March 2025
Department of Dermatology, The University of California, San Diego, USA.
Delayed inflammatory nodules (DIN) after soft-tissue filler injection may occur after infections, vaccinations, or procedures. We report a DIN from predominantly low-molecular-weight HA (PLMW-HA) filler secondary to COVID-19 infection that was resistant to conservative management, requiring intralesional combination therapy with triamcinolone, 5-fluorouracil, and recombinant human hyaluronidase for resolution.
View Article and Find Full Text PDFGlobal Algorithm for the Endovascular Treatment of Chronic Femoropopliteal Lesions: An Interdisciplinary Expert Opinion Statement.
JACC Cardiovasc Interv
March 2025
Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center, University of Duisburg-Essen, Essen, Germany.
A global treatment algorithm was developed for the endovascular revascularization of femoropopliteal lesions and chronic total occlusions, aiming toward a more standardized approach to endovascular treatment in patients with peripheral artery disease. The following steps are proposed. 1) Evaluation of lesion morphology based on preprocedural imaging by Duplex sonography and intravenous ultrasound for selection of lesion preparation tools.
View Article and Find Full Text PDFEfficacy of Acoramidis on All-Cause Mortality and Cardiovascular Hospitalization in Transthyretin Amyloid Cardiomyopathy.
J Am Coll Cardiol
March 2025
National Amyloidosis Centre, University College London, Royal Free Hospital, London, United Kingdom.
Background: Transthyretin amyloid cardiomyopathy (ATTR-CM) is an underdiagnosed chronic disease associated with progressive heart failure that results in impaired quality of life, repeated hospitalizations, and premature death. Acoramidis is a selective, oral transthyretin stabilizer recently approved by the U.S.
View Article and Find Full Text PDFStatus of temozolomide use without insurance coverage in patients with aggressive pituitary neuroendocrine tumors.
Endocr J
March 2025
Hypothalamic & Pituitary Center, Moriyama Memorial Hospital, Tokyo 134-0081, Japan.
The 2017 World Health Organization classification described aggressive pituitary neuroendocrine tumor (PitNET) as "a tumor with strong invasiveness and rapid growth, which is difficult to treat with surgery, radiation therapy, or drug therapy," which remains a challenge in the treatment of pituitary tumors. Currently, temozolomide (TMZ) is the first-line treatment for aggressive PitNET. However, it is not yet covered by insurance in Japan.
View Article and Find Full Text PDFSynergistic antibacterial effects of pinaverium bromide and oxacillin against .
Zhong Nan Da Xue Xue Bao Yi Xue Ban
October 2024
Department of Laboratory Medicine, Third Xiangya Hospital, Central South University, Changsha 410013, China.
Objectives: () adheres to the surface of medical devices, forming highly drug-resistant biofilms, which has made the development of novel antibacterial agents against and its biofilms a key research focus. By drug repurposing, this study aims to explore the combinational antimicrobial effects between pinaverium bromide (PVB), a -type calcium channel blocker, and oxacillin (OXA) against .
Methods: Clinical isolates of were collected from January to September 2022 at the Department of Clinical Laboratory of the Third Xiangya Hospital, Central South University.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!